Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.63 USD
Change Today -0.0312 / -0.67%
Volume 2.0K
As of 5:20 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

chembio diagnostics inc (CEMI) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/27/14 - $5.20
52 Week Low
05/8/14 - $2.83
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

chembio diagnostics inc (CEMI) Related Businessweek News

No Related Businessweek News Found

chembio diagnostics inc (CEMI) Details

Chembio Diagnostics, Inc., together with its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care diagnostic tests that detect infectious diseases. It offers rapid tests for the detection of HIV and syphilis antibodies. The company’s products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV Test, which detect antibodies to HIV 1 and 2 with visually interpreted results; a Syphilis multiplex test for the detection of antibodies to HIV and Syphilis; and a rapid test for the detection of Hepatitis-C antibodies. Chembio Diagnostics, Inc. sells its products under STAT PAK, SURE CHECK, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with the Oswaldo Cruz Foundation relating to products based on its DPP technology products; and the Centers for Disease Control and Prevention to develop and validate DPP Ebola and DPP Febrile Illness Assays. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

166 Employees
Last Reported Date: 03/5/15
Founded in 1985

chembio diagnostics inc (CEMI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $298.6K
Chief Operating Officer
Total Annual Compensation: $334.6K
Chief Science & Technology Officer
Total Annual Compensation: $405.0K
Compensation as of Fiscal Year 2014.

chembio diagnostics inc (CEMI) Key Developments

Chembio Diagnostics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Chembio Diagnostics, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, net product sales were $6,549,254 against $7,096,191 a year ago. Loss from operation was $672,176 against $176,042 a year ago. Net loss was $495,862 or $0.05 per diluted share against $261,987 or $0.03 per diluted share a year ago. Total revenues were $7.10 million, compared with $7.86 million a year ago. For the year, net product sales were $27,645,284 against $29,549,609 a year ago. Loss from operation was $1,550,253 against income from operation of $1,004,827 a year ago. Net loss was $1,137,203 or $0.12 per diluted share against net income of $530,818 or $0.06 per diluted share a year ago. Net cash used in operating activities were $320,299 against net cash provided by operating activities of $2,277,614 a year ago. Total revenues for 2014 represent a slight decrease as compared to 2013. This is due primarily to 2 factors. Chembio filled a single $5.3 million international STAT-PAK order in 2013, which did not recur in 2014. The final $660,000 shipment of product for that order took place in fourth quarter of 2013. Decrease in U.S. sales revenue of $2.3 million, due to termination of the STAT-PAK distribution agreement with Alere. The decrease was primarily due to net cash used in investing activities to fund deposits on, and purchase of fixed assets of $1.45 million as well as net cash used in operating activities of $3.82 million, which included an increase in accounts receivable of $3.77 million, an increase in inventories of $0.45 million and an increase in accounts payable, $0.64 million.

Chembio Diagnostics, Inc. to Report Fiscal Year 2014 Results on Mar 05, 2015

Chembio Diagnostics, Inc. announced that they will report fiscal year 2014 results at 9:00 AM, Eastern Standard Time on Mar 05, 2015

Chembio Diagnostics, Inc., 2014 Earnings Call, Mar 05, 2015

Chembio Diagnostics, Inc., 2014 Earnings Call, Mar 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEMI:US $4.63 USD -0.0312

CEMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $48.37 USD -0.66
OraSure Technologies Inc $6.16 USD +0.085
Trinity Biotech PLC $15.70 USD -0.20
View Industry Companies

Industry Analysis


Industry Average

Valuation CEMI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHEMBIO DIAGNOSTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at